28 September 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Purchase and Transfer of Shares and PDMR Shareholdings

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company announces that on 27 September 2021, Deborah Davis, the Chair of Diaceutics, purchased 17,800 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.11 pence per Ordinary Share.

In addition, Philip White transferred 150,000 Ordinary Shares to his father, Philip Michael White.

As a result of the purchase, Deborah's shareholding is 44,800 Ordinary Shares, representing approximately 0.05 % of the Company's issued share capital and as a result of Philip's transfer, the beneficial holding of Philip White will be 1,606,389 Ordinary Shares, representing 1.91 % of the Company's issued share capital.

Enquiries:

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.